
Veru (VERU) Stock Forecast & Price Target
Veru (VERU) Analyst Ratings
Bulls say
Veru Inc has demonstrated a robust cash position and notable financial performance, highlighted by net revenues of $16.9 million, reflecting a 4% year-over-year growth that exceeded projections and showcased the company's ability to generate revenue efficiently. The positive outlook is further supported by the anticipated reporting of topline data from the Phase 2b sarcopenic obesity trial in January 2025, which could facilitate partnerships for the enobosarm program aimed at obesity treatment. Additionally, the ease of administration of enobosarm as an oral drug offers a competitive advantage over alternatives requiring intravenous administration, potentially enhancing its market appeal and driving future growth.
Bears say
Veru Inc. is facing significant negative outlook factors, primarily due to a drastic reduction in its workforce from 210 to 22 employees following the sale of its UK and Malaysian subsidiaries, indicating potential operational instability. Furthermore, the company's drug, enobosarm, is subject to multiple investment risks including the possibility of failure in clinical trials for obesity treatment, challenges in obtaining regulatory approval, and uncertainties surrounding its commercial success related to reimbursement and competition. Additionally, concerns regarding dilution risk further complicate the investment landscape, exacerbating doubts about the company's financial health and growth prospects.
This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.
Veru (VERU) Analyst Forecast & Price Prediction
Start investing in Veru (VERU)
Order type
Buy in
Order amount
Est. shares
0 shares